Login to Your Account

Clinic Roundup

Thursday, April 5, 2012

• Enanta Pharmaceuticals Inc., of Watertown, Mass., reported Phase II data showing that different doses of ABT-450/r, its lead candidate in its hepatitis C virus (HCV) protease inhibitor collaboration with Abbott, of Abbott Park, Ill., plus ABT-333 and ribavirin administered for 12 weeks produced sustained virological response at 12 weeks post-treatment (SVR12) in 93 percent and 95 percent of treatment-naïve genotype 1 patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription